Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Artivion, Inc.

NYSE: AORT · Industrial Applications and Services · 1 alert · CIK 784199

Share price
$18.47Close, Nov 16
Market cap
$901M
Shares outstanding
48.79MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Artivion, Inc. filings on SEC EDGAR ↗

4:10 PM ET 8-K
Financial Results

Artivion Financial Results

Artivion reported Q3 2026 revenue of $123.8 million, a 9% increase year-over-year, driven by strong performance in On-X and stent grafts. The company narrowed its full-year 2026 revenue guidance to $484-$492 million and is preparing for the U.S. commercial launch of NEXUS in January 2027.

Term
Q3 2026

“In the third quarter of 2026, we delivered 9% constant currency revenue growth, reflecting continued execution of our strategy to drive long-term, profitable growth through an expanding and clinically differentiated product portfolio.”

Pat Mackin, Chairman, President, and Chief Executive Officer

“Overall, we are encouraged by our third quarter performance and the progress we have made so far in 2026. With the recent PMAs of AMDS and NEXUS in the U.S., and ARCEVO LSA on track with enrollment in the ARTIZEN IDE trial, we believe we are on track to being the only company with a comprehensive aortic arch portfolio, which represents an approximately $330 million annual U.S. market opportunity.”

Pat Mackin, Chairman, President, and Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.